BFA
AIMT

BlackRock Fund Advisors’s Aimmune Therapeutics AIMT Stock Holding History

BlackRock Fund Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$27.8M Buy
1,360,818
+696,072
+105% +$14.2M 0.01% 1995
2016
Q3 		$9.97M Buy
664,746
+42,183
+7% +$569K ﹤0.01% 2474
2016
Q2 		$6.74M Buy
622,563
+355,957
+134% +$4.84M ﹤0.01% 2633
2016
Q1 		$3.62M Sell
266,606
-14,348
-5% -$224K ﹤0.01% 2904
2015
Q4 		$5.18M Buy
280,954
+15,241
+6% +$282K ﹤0.01% 2823
2015
Q3 		$6.73M Buy
+265,713
New +$6.21M ﹤0.01% 2608

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

BlackRock Fund Advisors's AIMT Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Aimmune Therapeutics (AIMT) stake by 105% in Q4 2016, buying an estimated $14.2M and bringing the position to 1,360,818 shares worth $27.8M. The position accounts for 0.01% of the portfolio, ranked #1995.

BlackRock Fund Advisors first reported a position in AIMT in Q3 2015 and has held it in 6 quarters since. 92 funds tracked by Wall St. Rank hold AIMT as of Q4 2016.

  • BlackRock Fund Advisors held 1,360,818 shares of Aimmune Therapeutics worth $27.8M as of Q4 2016.
  • BlackRock Fund Advisors bought 696,072 Aimmune Therapeutics shares in Q4 2016, an estimated $14.2M.
  • Aimmune Therapeutics made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1995 holding.
  • BlackRock Fund Advisors first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • 92 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.